Bone Density Decline: Tenofovir is linked to a reduce in bone mineral density, growing the potential risk of bone challenges or fractures.HIV-1 contaminated subjects on dolutegravir monotherapy demonstrated immediate and dose-dependent reduction of antiviral exercise with declines of HIV-one RNA copies for each ml. The antiviral response was mainta